<div id="readability-page-1"><h3>Easter Sale - 70% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an update. Shanghai Henlius Biotech has secured Chinese regulatory approval to expand the indications of its rituximab biosimilar HANLIKANG, adding two combination therapies for adult patients with previously untreated and relapsed or refractory diffuse large B-cell lymphoma who are ineligible for stem cell transplantation. The decision broadens HANLIKANG’s clinical use across non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis, strengthening the company’s oncology franchise in a domestic rituximab market worth about RMB3.465 billion and offering more treatment options for lymphoma patients in China. HANLIKANG, already approved in the Chinese Mainland as well as in Nicaragua and Bolivia, can now be combined with polatuzumab vedotin plus chemotherapy in first-line DLBCL and with bendamustine and polatuzumab vedotin in difficult-to-treat relapsed or refractory cases. The expanded label is expected to enhance Henlius’s competitive position in China’s biologics market by leveraging a broader indication spectrum and potentially capturing greater share of the sizeable rituximab segment, benefiting both the company and its stakeholders through increased commercial opportunities and expanded patient access. The most recent analyst rating on (HK:2696) stock is a Buy with a HK$99.78 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page. More about Shanghai Henlius Biotech, Inc. Class H Shanghai Henlius Biotech, Inc. is a Chinese biopharmaceutical company focused on developing and commercializing therapeutic biological products, including biosimilars such as rituximab. Its flagship rituximab biosimilar, marketed as HANLIKANG, targets oncology and autoimmune indications in the Chinese Mainland and select international markets. Average Trading Volume: 1,147,828 Technical Sentiment Signal: Buy Current Market Cap: HK$43.07B </div>

513700

588250

516820

Shanghai Henlius Biotech, Inc. has received Chinese regulatory approval to expand the indications for its rituximab biosimilar, HANLIKANG. The approval allows for two new combination therapies for adult patients with untreated and relapsed or refractory diffuse large B-cell lymphoma. This expansion enhances Henlius's oncology portfolio in a market valued at approximately RMB3.465 billion, providing more treatment options for patients. The stock is currently rated as a Buy with a price target of HK$99.78, reflecting positive market sentiment.

Tip Ranks

Penghua CSI HK Connect Health Care Composite ETF

Penghua SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI 300 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai CSI Bio-medicine ETF

HENLIUS

Tianhong CNI BIOMEDICINE ETF

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Henlius Wins China Nod to Expand Indications for Rituximab Biosimilar HANLIKANG